Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents can in fact rise to the level of “co-scientists,” including Jure Leskovec, PhD, of Stanford...
Chenia Lloyd-Gascho, who was diagnosed with Li-Fraumeni syndrome when he was 8 years old, shared what it is like to grow up knowing you will one day get cancer, the routine monitoring recommended to...
Melanoma expert Ashani T. Weeraratna, PhD, of Johns Hopkins Bloomberg School of Public Health, explains how bemotrizinol—the first new sunscreen ingredient to be approved by the FDA in over 25 years—compares with currently used...
New studies show cancer vaccine promise despite funding cuts, and researchers identify protein signature that helps predict lung cancer risk.
AACR grant recipient Tae Hyun Hwang, PhD, of Vanderbilt University Medical Center, presented his work at the AACR Annual Meeting 2026 on AI agents that work together to assess how patients could respond to therapy and aid doctors in making cancer treatment decisions.
A targeted therapy nearly doubles overall survival in metastatic pancreatic cancer, and the FDA approves a bladder cancer treatment.
At the AACR Annual Meeting 2026, Lillian Siu shared her research into cancer interception and assembled a panel to discuss targeted cancer prevention.
At the AACR Annual Meeting 2026, researchers discussed the use of vaccines and aspirin to prevent cancer in people with Lynch syndrome.
ACS colorectal cancer screening guideline now includes a blood-based test, and GLP-1 therapies may reduce risk for cancer progression.
In May, AACR's journals editors highlighted studies on CD28’s impact on CAR T-cell activity, the relationship between neurons and pancreatic cancer, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More